NuCana plc (NASDAQ:NCNA – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 219,500 shares, a growth of 15.0% from the August 15th total of 190,800 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average daily volume of 301,300 shares, the days-to-cover ratio is presently 0.7 days.
Hedge Funds Weigh In On NuCana
A number of institutional investors and hedge funds have recently modified their holdings of the business. Opaleye Management Inc. boosted its holdings in shares of NuCana by 147.9% during the 4th quarter. Opaleye Management Inc. now owns 1,189,000 shares of the company’s stock worth $2,830,000 after buying an additional 709,400 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of NuCana by 163.2% during the 1st quarter. Acadian Asset Management LLC now owns 522,532 shares of the company’s stock worth $520,000 after buying an additional 324,010 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of NuCana by 10.4% during the 2nd quarter. Renaissance Technologies LLC now owns 371,433 shares of the company’s stock worth $269,000 after buying an additional 35,100 shares in the last quarter. Virtu Financial LLC boosted its holdings in shares of NuCana by 167.8% during the 1st quarter. Virtu Financial LLC now owns 77,952 shares of the company’s stock worth $78,000 after buying an additional 48,845 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. bought a new position in shares of NuCana during the 2nd quarter worth approximately $36,000. 32.85% of the stock is currently owned by institutional investors.
NuCana Stock Performance
NASDAQ:NCNA opened at $1.50 on Friday. The company has a market capitalization of $78.27 million, a PE ratio of -1.74 and a beta of 1.27. The company has a 50 day simple moving average of $1.58 and a two-hundred day simple moving average of $1.06. NuCana has a fifty-two week low of $0.52 and a fifty-two week high of $3.32.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer.
- Get a free copy of the StockNews.com research report on NuCana (NCNA)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.